Studies related to Constipation and Lactobacillus reuteri

Prophylactic Use Of A Probiotic In The Prevention Of Colic, Regurgitation, And Functional Constipation: A Randomized Clinical Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 468
Gender Both Genders
Age Range 0-1
Body Types Average
Notes for this study:
Administration of _l. reuteri_ DSM 17938 to infants during the first three months of life greatly reduced the occurrence of infantile colic relative to placebo, and also improve gastrointestinal symptoms such as increasing bowel evacuations (reducing risk of constipation) and regurgitations.

Ultimately, prophylactic treatment of infants with DSM 17938 resulted in less pediatric department visits and was estimated to save both parent and community over $200 (USD).

Lactobacillus Reuteri (DSM 17938) In Infants With Functional Chronic Constipation: A Double-blind, Randomized, Placebo-controlled Study

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 44
Gender Both Genders
Age Range 0-1
Notes for this study:
_L. reuteri_ DSM 17938 (10^8^ CFU) in infants who are at least six months old but suffering from constipation noted that supplementation was able to increase bowel frequency at all tested time points (2, 4, and 8 weeks) relative to placebo treatment; stool consistency appeared to soften over the course of the 8 weeks of supplementation, but the softening was not significantly different than placebo.

The instances of inconsolable crying during this time did not differ between groups as both increased over the study period.